Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.45 |
| ▸ | ABHD6 | Q9BV23 | 6/20 | 0.43 |
| ▸ | HTR5A | P47898 | 5/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17114724 | 0.94 | ESR1 (0.45) | ESR1ESR2ABHD6HTR5AEP300 | |
| SCHEMBL28901664 | 0.84 | HTR5A (0.40) | ABHD6HTR5APTGDR2 | |
| SCHEMBL19693487 | 0.83 | ABHD6 (0.44) | ESR1ESR2ABHD6EP300CREBBP | |
| SCHEMBL17798326 | 0.80 | ESR1 (0.45) | ESR1ESR2ABHD6EP300CREBBP | |
| SCHEMBL506312 | 0.79 | ESR1 (0.43) | ESR1ESR2ABHD6EP300CREBBP | |
| SCHEMBL22981209 | 0.79 | ESR1 (0.53) | ESR1ESR2ABHD6PKM | |
| SCHEMBL19643352 | 0.79 | ESR1 (0.53) | ESR1ESR2ABHD6HTR5AEP300 | |
| SCHEMBL17114829 | 0.79 | ESR1 (0.44) | ESR1ESR2ABHD6HTR5AEP300 | |
| SCHEMBL31163315 | 0.79 | ESR2 (0.47) | ESR2ABHD6 | |
| SCHEMBL587897 | 0.77 | ABHD6 (0.69) | ESR1ESR2ABHD6HTR5AEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024046221-A1 | EGFR INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-03-07 | — | — | WO | disclosed |